A pathway proteomic profile of ischemic stroke survivors reveals innate immune dysfunction in association with mild symptoms of depression - a pilot study

Frontiers in Neurology

Volumn 7, Issue JUN, 2016, Pages

  Nguyen, Vinh A ^a,b   Carey, Leeanne M ^a,b   Giummarra, Loretta ^a   Faou, Pierre ^a   Cooke, Ira ^a   Howells, David W ^c   Tse, Tamara ^a,b   Macaulay, S Lance ^d   Ma, Henry ^b,e   Davis, Stephen M ^f,g   Donnan, Geoffrey A ^b,f   Crewther, Sheila G ^a,b  

^a LA TROBE UNIVERSITY   (Australia)

^b FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^c UNIVERSITY OF TASMANIA   (Australia)

^d CSIRO   (Australia)

^e MONASH UNIVERSITY   (Australia)

^f UNIVERSITY OF MELBOURNE   (Australia)

^g ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

Blood biomarkers; Complement and coagulation; Immunity and inflammation; Ischemic stroke; Post stroke depression; Proteomics; Stroke neurological recovery

Indexed keywords

PROTEOME;

ADAPTIVE IMMUNITY; ADULT; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CLINICAL ARTICLE; CONVALESCENCE; DISEASE ASSOCIATION; DOWN REGULATION; FEMALE; HUMAN; IMMUNE DYSREGULATION; INNATE IMMUNITY; MALE; PILOT STUDY; PROTEIN BLOOD LEVEL; PROTEOMICS; SURVIVOR;

EID: 84977670376     PISSN: None     EISSN: 16642295     Source Type: Journal    
DOI: 10.3389/fneur.2016.00085     Document Type: Article

References (140)

1. Corbyn Z. Stroke: a growing global burden. Nature (2014) 510(7506):S2-3. doi:10.1038/510S2a
2. Hackett ML, Yapa C, Parag V, Anderson CS. Frequency of depression after stroke: a systematic review of observational studies. Stroke (2005) 36(6):1330-40. doi:10.1161/01.str.0000165928.19135.35
3. Whyte EM, Mulsant BH. Post stroke depression: epidemiology, pathophysiology, and biological treatment. Biol Psychiatry (2002) 52(3):253-64. doi:10.1016/S0006-3223(02)01424-5
4. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5®). Washington, DC: American Psychiatric Association (2013).
5. Paolucci S. Epidemiology and treatment of post-stroke depression. Neuropsychiatr Dis Treat (2008) 4(1):145-54. doi:10.2147/NDT.S2017
6. Ahn D-H, Lee Y-J, Jeong J-H, Kim Y-R, Park J-B. The effect of post-stroke depression on rehabilitation outcome and the impact of caregiver type as a factor of post-stroke depression. Ann Rehabil Med (2015) 39(1):74-80. doi:10.5535/arm.2015.39.1.74
7. Schmid AA, Kroenke K, Hendrie HC, Bakas T, Sutherland JM, Williams LS. Poststroke depression and treatment effects on functional outcomes. Neurology (2011) 76(11):1000-5. doi:10.1212/WNL.0b013e318210435e
8. Pascoe MC, Crewther SG, Carey LM, Crewther DP. Inflammation and depression: why poststroke depression may be the norm and not the exception. Int J Stroke (2011) 6(2):128-35. doi:10.1111/j.1747-4949.2010.00565.x
9. Robinson RG, Szetela B. Mood change following left hemispheric brain injury. Ann Neurol (1981) 9(5):447-53. doi:10.1002/ana.410090506
10. Vataja R, Leppävuori A, Pohjasvaara T, Mäntylä R, Aronen HJ, Salonen O, et al. Poststroke depression and lesion location revisited. J Neuropsychiatry Clin Neurosci (2004) 16(2):156-62. doi:10.1176/jnp.16.2.156
11. Tang W, Chen Y, Lu J, Chu WC, Mok V, Ungvari GS, et al. White matter hyperintensities in post-stroke depression: a case control study. J Neurol Neurosurg Psychiatry (2010) 81(12):1312-5. doi:10.1136/jnnp.2009.203141
12. Mitra J, Shen K-K, Ghose S, Bourgeat P, Fripp J, Salvado O, et al. Predicting poststroke depression from brain connectivity. In: O'Donnell L, Nedjati-Gilani G, Rathi Y, Reisert M, Schneider T, editors. Computational Diffusion MRI. Boston: Springer International Publishing (2014). p. 89-99.
13. Zubarev RA. The challenge of the proteome dynamic range and its implications for in-depth proteomics. Proteomics (2013) 13(5):723-6. doi:10.1002/pmic.201200451
14. Loubinoux I, Kronenberg G, Endres M, Schumann-Bard P, Freret T, Filipkowski RK, et al. Post-stroke depression: mechanisms, translation and therapy. J Cell Mol Med (2012) 16(9):1961-9. doi:10.1111/j.1582-4934.2012.01555.x
15. Robinson RG, Shoemaker WJ, Schlumpf M, Valk T, Bloom FE. Effect of experimental cerebral infarction in rat brain on catecholamine and behaviour. Nature (1975) 255(5506):332-4. doi:10.1038/255332a0
16. Perini F, Morra M, Alecci M, Galloni E, Marchi M, Toso V. Temporal profile of serum anti-inflammatory and pro-inflammatory interleukins in acute ischemic stroke patients. Neurol Sci (2001) 22(4):289-96. doi:10.1007/s10072-001-8170-y
17. Vu NQ, Aizenstein HJ. Depression in the elderly: brain correlates, neuropsychological findings, and role of vascular lesion load. Curr Opin Neurol (2013) 26(6):656-61. doi:10.1097/wco.0000000000000028
18. Broomfield NM, Quinn TJ, Abdul-Rahim AH, Walters MR, Evans JJ. Depression and anxiety symptoms post-stroke/TIA: prevalence and associations in cross-sectional data from a regional stroke registry. BMC Neurol (2014) 14:198. doi:10.1186/s12883-014-0198-8
19. El Husseini N, Goldstein LB, Peterson ED, Zhao X, Pan W, Olson DM, et al. Depression and antidepressant use after stroke and transient ischemic attack. Stroke (2012) 43(6):1609-16. doi:10.1161/strokeaha.111.643130
20. Luijendijk HJ, Stricker BHC, Wieberdink RG, Koudstaal PJ, Hofman A, Breteler MM, et al. Transient ischemic attack and incident depression. Stroke (2011) 42(7):1857-61. doi:10.1161/strokeaha.110.604405
21. Rao R, Jackson S, Howard R. Depression in older people with mild stroke, carotid stenosis and peripheral vascular disease: a comparison with healthy controls. Int J Geriatr Psychiatry (2001) 16(2):175-83. doi:10.1002/1099-1166(200102)16:2<175:AID-GPS298>3.0.CO;2-0
22. Spalletta G, Bossu P, Ciaramella A, Bria P, Caltagirone C, Robinson RG. The etiology of poststroke depression: a review of the literature and a new hypothesis involving inflammatory cytokines. Mol Psychiatry (2006) 11(11):984-91. doi:10.1038/sj.mp.4001879
23. Vogelgesang A, May VEL, Grunwald U, Bakkeboe M, Langner S, Wallaschofski H, et al. Functional status of peripheral blood T-cells in ischemic stroke patients. PLoS One (2010) 5(1):e8718. doi:10.1371/journal.pone.0008718
24. Hama S, Yamashita H, Yamawaki S, Kurisu K. Post-stroke depression and apathy: interactions between functional recovery, lesion location, and emotional response. Psychogeriatrics (2011) 11(1):68-76. doi:10.1111/j.1479-8301.2011.00358.x
25. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry (2010) 67(5):446-57. doi:10.1016/j.biopsych.2009.09.033
26. Galea J, Brough D. The role of inflammation and interleukin-1 in acute cerebrovascular disease. J Inflam Res (2013) 6:121-8. doi:10.2147/JIR.S35629
27. Kim J-M, Stewart R, Kim S-W, Shin I-S, Kim J-T, Park M-S, et al. Associations of cytokine gene polymorphisms with post-stroke depression. World J Biol Psychiatry (2011) 13(8):579-87. doi:10.3109/15622975.2011.588247
28. Noonan K, Carey LM, Crewther SG. Meta-analyses indicate associations between neuroendocrine activation, deactivation in neurotrophic and neuroimaging markers in depression after stroke. J Stroke Cerebrovasc Dis (2013) 22(7):e124-35. doi:10.1016/j.jstrokecerebrovasdis.2012.09.008
29. Lambertsen KL, Biber K, Finsen B. Inflammatory cytokines in experimental and human stroke. J Cereb Blood Flow Metab (2012) 32(9):1677-98. doi:10.1038/jcbfm.2012.88
30. Worthmann H, Tryc AB, Goldbecker A, Ma YT, Tountopoulou A, Hahn A, et al. The temporal profile of inflammatory markers and mediators in blood after acute ischemic stroke differs depending on stroke outcome. Cerebrovasc Dis (2010) 30(1):85-92. doi:10.1159/000314624
31. Su J-A, Chou S-Y, Tsai C-S, Hung T-H. Cytokine changes in the pathophysiology of poststroke depression. Gen Hosp Psychiatry (2012) 34(1):35-9. doi:10.1016/j.genhosppsych.2011.09.020
32. Leonard B, Maes M. Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci Biobehav Rev (2012) 36(2):764-85. doi:10.1016/j.neubiorev.2011.12.005
33. Maes M. Depression is an inflammatory disease, but cell-mediated immune activation is the key component of depression. Prog Neuropsychopharmacol Biol Psychiatry (2011) 35(3):664-75. doi:10.1016/j.pnpbp.2010.06.014
34. Zunszain PA, Anacker C, Cattaneo A, Carvalho LA, Pariante CM. Glucocorticoids, cytokines and brain abnormalities in depression. Prog Neuropsychopharmacol Biol Psychiatry (2011) 35(3):722-9. doi:10.1016/j.pnpbp.2010.04.011
35. Wetie AN, Woods A, Darie C. Mass spectrometric analysis of post-translational modifications (PTMs) and protein-protein interactions (PPIs). In: Woods AG, Darie CC, editors. Advancements of Mass Spectrometry in Biomedical Research (Vol. 806), Cham: Springer International Publishing (2014). p. 205-35.
36. Sharma P, Cosme J, Gramolini AO. Recent proteomic advances in cardiac cells. J Proteomics (2013) 81:3-14. doi:10.1016/j.jprot.2012.10.026
37. Koomen JM, Haura EB, Bepler G, Sutphen R, Remily-Wood ER, Benson K, et al. Proteomic contributions to personalized cancer care. Mol Cell Proteomics (2008) 7(10):1780-94. doi:10.1074/mcp. R800002-MCP200
38. Giardina BJ, Stanley BA, Chiang H-L. Glucose induces rapid changes in the secretome of Saccharomyces cerevisiae. Proteome Sci (2014) 12(1):9. doi:10.1186/1477-5956-12-9
39. Pavlov MY, Ehrenberg M. Optimal control of gene expression for fast proteome adaptation to environmental change. Proc Natl Acad Sci U S A (2013) 110(51):20527-32. doi:10.1073/pnas.1309356110
40. Kumar Y, Liang C, Bo Z, Rajapakse JC, Ooi EE, Tannenbaum SR. Serum proteome and cytokine analysis in a longitudinal cohort of adults with primary dengue infection reveals predictive markers of DHF. PLoS Negl Trop Dis (2012) 6(11):e1887. doi:10.1371/journal.pntd.0001887
41. Wildsmith KR, Schauer SP, Smith AM, Arnott D, Zhu Y, Haznedar J, et al. Identification of longitudinally dynamic biomarkers in Alzheimer's disease cerebrospinal fluid by targeted proteomics. Mol Neurodegener (2014) 9(1):1-14. doi:10.1186/1750-1326-9-22
42. Ning M, Lopez M, Cao J, Buonanno FS, Lo EH. Application of proteomics to cerebrovascular disease. Electrophoresis (2012) 33:24. doi:10.1002/elps.201200481
43. Lopez MF, Sarracino DA, Prakash A, Athanas M, Krastins B, Rezai T, et al. Discrimination of ischemic and hemorrhagic strokes using a multiplexed, mass spectrometry-based assay for serum apolipoproteins coupled to multi-marker ROC algorithm. Proteomics Clin Appl (2012) 6(3-4):190-200. doi:10.1002/prca.201100041
44. Sharma R, Gowda H, Chavan S, Advani J, Kelkar D, Kumar GSS, et al. Proteomic signature of endothelial dysfunction identified in the serum of acute ischemic stroke patients by the iTRAQ-based LC-MS approach. J Proteome Res (2015) 14(6):2466-79. doi:10.1021/pr501324n
45. Ning M, Sarracino DA, Buonanno FS, Krastins B, Chou S, McMullin D, et al. Proteomic protease substrate profiling of tPA treatment in acute ischemic stroke patients: a step toward individualizing thrombolytic therapy at the bedside. Transl Stroke Res (2010) 1(4):268-75. doi:10.1007/s12975-010-0047-z
46. Pan S, Zhan X, Su X, Guo L, Lv L, Su B. Proteomic analysis of serum proteins in acute ischemic stroke patients treated with acupuncture. Exp Biol Med (2011) 236(3):325-33. doi:10.1258/ebm.2011.010041
47. Zhan Y, Yang YT, You HM, Cao D, Liu CY, Zhou CJ, et al. Plasma-based proteomics reveals lipid metabolic and immunoregulatory dysregulation in post-stroke depression. Eur Psychiatry (2014) 29(5):307-15. doi:10.1016/j.eurpsy.2014.03.004
48. Pottiez G, Wiederin J, Fox HS, Ciborowski P. Comparison of 4-plex to 8-plex iTRAQ quantitative measurements of proteins in human plasma samples. J Proteome Res (2012) 11(7):3774-81. doi:10.1021/pr300414z
49. Ross PL, Huang YN, Marchese JN, Williamson B, Parker K, Hattan S, et al. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol Cell Proteomics (2004) 3(12):1154-69. doi:10.1074/mcp. M400129-MCP200
50. Janeway CA, Travers P, Walport M, Mark S. Immunobiology: The Immune System in Health and Disease. 5th ed. New York: Garland Science (2001).
51. Pekna M, Pekny M. The neurobiology of brain injury. Cerebrum (2012) 2012:9.
52. Neilson KA, Ali NA, Muralidharan S, Mirzaei M, Mariani M, Assadourian G, et al. Less label, more free: approaches in label-free quantitative mass spectrometry. Proteomics (2011) 11(4):535-53. doi:10.1002/pmic.201000553
53. Wang H, Alvarez S, Hicks LM. Comprehensive comparison of iTRAQ and label-free LC-based quantitative proteomics approaches using two Chlamydomonas reinhardtii strains of interest for biofuels engineering. J Proteome Res (2012) 11(1):487-501. doi:10.1021/pr2008225
54. Trinh HV, Grossmann J, Gehrig P, Roschitzki B, Schlapbach R, Greber UF, et al. iTRAQ-based and label-free proteomics approaches for studies of human adenovirus infections. Int J Proteomics (2013) 2013:16. doi:10.1155/2013/581862
55. Jambunathan K, Galande AK. Sample collection in clinical proteomics-proteolytic activity profile of serum and plasma. Proteomics Clin Appl (2014) 8(5-6):299-307. doi:10.1002/prca.201300037
56. Atala A. Methods of Tissue Engineering. Cambridge, MA: Gulf Professional Publishing (2002).
57. Yi J, Kim C, Gelfand CA. Inhibition of intrinsic proteolytic activities moderates preanalytical variability and instability of human plasma. J Proteome Res (2007) 6(5):1768-81. doi:10.1021/pr060550h
58. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 102(43):15545-50. doi:10.1073/pnas.0506580102
59. Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc (2008) 4(1):44-57. doi:10.1038/nprot.2008.211
60. Käll L, Vitek O. Computational mass spectrometry-based proteomics. PLoS Comput Biol (2011) 7(12):e1002277. doi:10.1371/journal.pcbi.1002277
61. Schmidt A, Forne I, Imhof A. Bioinformatic analysis of proteomics data. BMC Syst Biol (2014) 8(Suppl 2):S3. doi:10.1186/1752-0509-8-S2-S3
62. Sridhar S, Schembri F, Zeskind J, Shah V, Gustafson AM, Steiling K, et al. Smoking-induced gene expression changes in the bronchial airway are reflected in nasal and buccal epithelium. BMC Genomics (2008) 9(1):259. doi:10.1186/1471-2164-9-259
63. Wu X, Hasan MA, Chen JY. Pathway and network analysis in proteomics. J Theor Biol (2014) 362:44-52. doi:10.1016/j.jtbi.2014.05.031
64. Carey LM, Crewther S, Salvado O, Lindén T, Connelly A, Wilson W, et al. STroke imAging pRevention and treatment (START): a longitudinal stroke cohort study: clinical trials protocol. Int J Stroke (2015) 10(4):636-44. doi:10.1111/ijs.12190
65. Ma H, Parsons MW, Christensen S, Campbell BCV, Churilov L, Connelly A, et al. A multicentre, randomized, double-blinded, placebo-controlled phase III study to investigate extending the time for thrombolysis in emergency neurological deficits (EXTEND). Int J Stroke (2012) 7(1):74-80. doi:10.1111/j.1747-4949.2011.00730.x
66. Brott T, Adams HP, Olinger CP, Marler JR, Barsan WG, Biller J, et al. Measurements of acute cerebral infarction: a clinical examination scale. Stroke (1989) 20(7):864-70. doi:10.1161/01.str.20.7.864
67. Kroenke K, Spitzer RL, Williams JB. The patient health questionnaire-2: validity of a two-item depression screener. Med Care (2003) 41(11):1284-92. doi:10.1097/01.MLR.0000093487.78664.3C
68. Kroenke K, Spitzer RL, Williams JBW. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med (2001) 16(9):606-13. doi:10.1046/j.1525-1497.2001.016009606.x
69. Janneke M, Gooskens F, Schepers VP, Schuurmans MJ, Lindeman E, Hafsteinsdóttir TB. Screening for poststroke depression using the patient health questionnaire. Nurs Res (2012) 61(5):333-41. doi:10.1097/NNR.0b013e31825d9e9e
70. Fantino B, Moore N. The self-reported Montgomery-Åsberg depression rating scale is a useful evaluative tool in major depressive disorder. BMC Psychiatry (2009) 9(1):26. doi:10.1186/1471-244X-9-26
71. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry (1979) 134(4):382-9. doi:10.1192/bjp.134.4.382
72. Williams JBW, Kobak KA. Development and reliability of a structured interview guide for the Montgomery-Åsberg Depression Rating Scale (SIGMA). Br J Psychiatry (2008) 192:52-8. doi:10.1192/bjp.bp.106.032532
73. Dong Y, Sharma VK, Chan BP-L, Venketasubramanian N, Teoh HL, Seet RCS, et al. The Montreal Cognitive Assessment (MoCA) is superior to the mini-mental state examination (MMSE) for the detection of vascular cognitive impairment after acute stroke. J Neurol Sci (2010) 299(1):15-8. doi:10.1016/j.jns.2010.08.051
74. Cumming TB, Churilov L, Linden T, Bernhardt J. Montreal cognitive assessment and mini-mental state examination are both valid cognitive tools in stroke. Acta Neurol Scand (2013) 128(2):122-9. doi:10.1111/ane.12084
75. Rankin J. Cerebral vascular accidents in patients over the age of 60. II. Prognosis. Scott Med J (1957) 2(5):200.
76. Ishihama Y, Rappsilber J, Mann M. Modular stop and go extraction tips with stacked disks for parallel and multidimensional peptide fractionation in proteomics. J Proteome Res (2006) 5(4):988-94. doi:10.1021/pr050385q
77. Cox J, Mann M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat Biotech (2008) 26:1367-72. doi:10.1038/nbt.1511
78. Cho H, Smalley DM, Theodorescu D, Ley K, Lee JK. Statistical identification of differentially labeled peptides from liquid chromatography tandem mass spectrometry. Proteomics (2007) 7(20):3681-92. doi:10.1002/pmic.200601034
79. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. Gene ontology: tool for the unification of biology. Nat Genet (2000) 25(1):25-9. doi:10.1038/75556
80. Kanehisa M, Goto S, Kawashima S, Nakaya A. The KEGG databases at GenomeNet. Nucleic Acids Res (2002) 30(1):42-6. doi:10.1093/nar/30.1.42
81. Nishimura D. BioCarta. Biotech Softw Internet Rep (2001) 2(3):117-20. doi:10.1089/152791601750294344
82. Croft D, Mundo AF, Haw R, Milacic M, Weiser J, Wu G, et al. The reactome pathway knowledgebase. Nucleic Acids Res (2014) 42(Database issue):D472-7. doi:10.1093/nar/gkt1102
83. Eyre TA, Ducluzeau F, Sneddon TP, Povey S, Bruford EA, Lush MJ. The HUGO gene nomenclature database, 2006 updates. Nucleic Acids Res (2006) 34(Suppl 1):D319-21. doi:10.1093/nar/gkj147
84. Lee S, Shafe AC, Cowie MR. UK stroke incidence, mortality and cardiovascular risk management 1999-2008: time-trend analysis from the general practice research database. BMJ Open (2011) 1(2):e000269. doi:10.1136/bmjopen-2011-000269
85. Adams HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in acute stroke treatment. Stroke (1993) 24(1):35-41. doi:10.1161/01.str.24.1.35
86. Sagen U, Vik TG, Moum T, Mørland T, Finset A, Dammen T. Screening for anxiety and depression after stroke: comparison of the hospital anxiety and depression scale and the Montgomery and Åsberg Depression Rating Scale. J Psychosom Res (2009) 67(4):325-32. doi:10.1016/j.jpsychores.2009.03.007
87. Hart A. Mann-Whitney test is not just a test of medians: differences in spread can be important. BMJ (2001) 323(7309):391-3. doi:10.1136/bmj.323.7309.391
88. Chiu C-C, Huang C-C, Chan W-L, Chung C-M, Huang P-H, Lin S-J, et al. Increased risk of ischemic stroke in patients with systemic lupus erythematosus: a nationwide population-based study. Intern Med (2012) 51(1):17-21. doi:10.2169/internalmedicine.51.6154
89. Bradley DT, Zipfel PF, Hughes AE. Complement in age-related macular degeneration: a focus on function. Eye (2011) 25(6):683-93. doi:10.1038/eye.2011.37
90. Zhang B, Ramesh G, Uematsu S, Akira S, Reeves WB. TLR4 signaling mediates inflammation and tissue injury in nephrotoxicity. J Am Soc Nephrol (2008) 19(5):923-32. doi:10.1681/asn.2007090982
91. Fujita T. Evolution of the lectin-complement pathway and its role in innate immunity. Nat Rev Immunol (2002) 2(5):346-53. doi:10.1038/nri800
92. Collard CD, Väkevä A, Morrissey MA, Agah A, Rollins SA, Reenstra WR, et al. Complement activation after oxidative stress: role of the lectin complement pathway. Am J Pathol (2000) 156(5):1549-56. doi:10.1016/S0002-9440(10)65026-2
93. Roos A, Bouwman LH, van Gijlswijk-Janssen DJ, Faber-Krol MC, Stahl GL, Daha MR. Human IgA activates the complement system via the mannan-binding lectin pathway. J Immunol (2001) 167(5):2861-8. doi:10.4049/jimmunol.167.5.2861
94. Meijer B, Gearry R, Day A. The role of S100A12 as a systemic marker of inflammation. Int J Inflam (2012) 2012:907078. doi:10.1155/2012/907078
95. Stankovic S, Majkic-Singh N. Genetic aspects of ischemic stroke: coagulation, homocysteine, and lipoprotein metabolism as potential risk factors. Crit Rev Clin Lab Sci (2010) 47(2):72-123. doi:10.3109/10408361003791520
96. Fassbender K, Dempfle C-E, Mielke O, Schwartz A, Daffertshofer M, Eschenfelder C, et al. Changes in coagulation and fibrinolysis markers in acute ischemic stroke treated with recombinant tissue plasminogen activator. Stroke (1999) 30(10):2101-4. doi:10.1161/01.str.30.10.2101
97. Uchiyama S, Yamazaki M, Hara Y, Iwata M. Alterations of platelet, coagulation, and fibrinolysis markers in patients with acute ischemic stroke. Semin Thromb Hemost (1997) 23(6):535-41. doi:10.1055/s-2007-996132
98. SofiF, Cesari F, Abbate R, Gensini GF, Broze G, Fedi S. A meta-analysis of potential risks of low levels of protein Z for diseases related to vascular thrombosis. Thromb Haemost (2010) 103(4):749-56. doi:10.1160/TH09-09-0645
99. Chou SH-Y, Lee P-S, Konigsberg RG, Gallacci D, Chiou T, Arai K, et al. Plasma-type gelsolin is decreased in human blood and cerebrospinal fluid after subarachnoid hemorrhage. Stroke (2011) 42(12):3624-7. doi:10.1161/strokeaha.111.631135
100. Amara U, Rittirsch D, Flierl M, Bruckner U, Klos A, Gebhard F, et al. Interaction between the coagulation and complement system. Adv Exp Med Biol (2008) 632:71-9.
101. Delvaeye M, Conway EM. Coagulation and innate immune responses: can we view them separately? Blood (2009) 114(12):2367-74. doi:10.1182/blood-2009-05-199208
102. Markiewski MM, Nilsson B, Nilsson Ekdahl K, Mollnes TE, Lambris JD. Complement and coagulation: strangers or partners in crime? Trends Immunol (2007) 28(4):184-92. doi:10.1016/j.it.2007.02.006
103. Agarwal V, Talens S, Grandits AM, Blom AM. A novel interaction between complement inhibitor C4b-binding protein and plasminogen that enhances plasminogen activation. J Biol Chem (2015) 290(30):18333-42. doi:10.1074/jbc. M114.619494
104. Amara U, Flierl MA, Rittirsch D, Klos A, Chen H, Acker B, et al. Molecular intercommunication between the complement and coagulation systems. J Immunol (2010) 185(9):5628-36. doi:10.4049/jimmunol.0903678
105. Esmon CT, Xu J, Lupu F. Innate immunity and coagulation. J Thromb Haemost (2011) 9(Suppl 1):182-8. doi:10.1111/j.1538-7836.2011.04323.x
106. Chen GY, Nuñez G. Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol (2010) 10(12):826-37. doi:10.1038/nri2873
107. Gelderblom M, Sobey CG, Kleinschnitz C, Magnus T. Danger signals in stroke. Ageing Res Rev (2015) 24(Pt A):77-82. doi:10.1016/j.arr.2015.07.004
108. Kono H, Rock KL. How dying cells alert the immune system to danger. Nat Rev Immunol (2008) 8(4):279-89. doi:10.1038/nri2215
109. Shichita T, Ito M, Yoshimura A. Post-ischemic inflammation regulates neural damage and protection. Front Cell Neurosci (2014) 8:319. doi:10.3389/fncel.2014.00319
110. Sharp FR, Jickling GC, Stamova B, Tian Y, Zhan X, Liu D, et al. Molecular markers and mechanisms of stroke: RNA studies of blood in animals and humans. J Cereb Blood Flow Metab (2011) 31(7):1513-31. doi:10.1038/jcbfm.2011.45
111. Xu H, Tang Y, Liu D-Z, Ran R, Ander BP, Apperson M, et al. Gene expression in peripheral blood differs after cardioembolic compared with large-vessel atherosclerotic stroke: biomarkers for the etiology of ischemic stroke. J Cereb Blood Flow Metab (2008) 28(7):1320-8. doi:10.1038/jcbfm.2008.22
112. Fang J, Cheng Q. Etiological mechanisms of post-stroke depression: a review. Neurol Res (2009) 31(9):904-9. doi:10.1179/174313209X385752
113. Pan W, Stone KP, Hsuchou H, Manda VK, Zhang Y, Kastin AJ. Cytokine signaling modulates blood-brain barrier function. Curr Pharm Des (2011) 17(33):3729-40. doi:10.2174/138161211798220918
114. St-Amour I, Paré I, Alata W, Coulombe K, Ringuette-Goulet C, Drouin-Ouellet J, et al. Brain bioavailability of human intravenous immunoglobulin and its transport through the murine blood-brain barrier. J Cereb Blood Flow Metab (2013) 33(12):1983-92. doi:10.1038/jcbfm.2013.160
115. Famakin BM. The immune response to acute focal cerebral ischemia and associated post-stroke immunodepression: a focused review. Aging Dis (2014) 5(5):307-26. doi:10.14336/AD.2014.0500307
116. Macrez R, Ali C, Toutirais O, Le MauffB, Defer G, Dirnagl U, et al. Stroke and the immune system: from pathophysiology to new therapeutic strategies. Lancet Neurol (2011) 10(5):471-80. doi:10.1016/S1474-4422(11)70066-7
117. Dirnagl U, Klehmet J, Braun JS, Harms H, Meisel C, Ziemssen T, et al. Stroke-induced immunodepression: experimental evidence and clinical relevance. Stroke (2007) 38(2):770-3. doi:10.1161/01.STR.0000251441.89665.bc
118. Offner H, Vandenbark AA, Hurn PD. Effect of experimental stroke on peripheral immunity: CNS ischemia induces profound immunosuppression. Neuroscience (2009) 158(3):1098-111. doi:10.1016/j.neuroscience.2008.05.033
119. Kamel H, Iadecola C. Brain-immune interactions and ischemic stroke: clinical implications. Arch Neurol (2012) 69(5):576-81. doi:10.1001/archneurol.2011.3590
120. Kubera M, Obuchowicz E, Goehler L, Brzeszcz J, Maes M. In animal models, psychosocial stress-induced (neuro)inflammation, apoptosis and reduced neurogenesis are associated to the onset of depression. Prog Neuropsychopharmacol Biol Psychiatry (2011) 35(3):744-59. doi:10.1016/j.pnpbp.2010.08.026
121. Abbott NJ. Inflammatory mediators and modulation of blood-brain barrier permeability. Cell Mol Neurobiol (2000) 20(2):131-47. doi:10.1023/A:1007074420772
122. Emsley HC, Hopkins SJ. Post-stroke immunodepression and infection: an emerging concept. Infect Disord Drug Targets (2010) 10(2):91-7. doi:10.2174/187152610790963528
123. Urra X, Miró F, Chamorro A, Planas AM. Antigen-specific immune reactions to ischemic stroke. Front Cell Neurosci (2014) 8:278. doi:10.3389/fncel.2014.00278
124. Shinjyo N, Ståhlberg A, Dragunow M, Pekny M, Pekna M. Complement-derived anaphylatoxin C3a regulates in vitro differentiation and migration of neural progenitor cells. Stem Cells (2009) 27(11):2824-32. doi:10.1002/stem.225
125. Kim GH, Mocco J, Hahn DK, Kellner CP, Komotar RJ, Ducruet AF, et al. Protective effect of C5a receptor inhibition after murine reperfused stroke. Neurosurgery (2008) 63(1):122-6. doi:10.1227/01.NEU.0000335079.70222.8D
126. Arumugam TV, WoodruffTM, Lathia JD, Selvaraj PK, Mattson MP, Taylor SM. Neuroprotection in stroke by complement inhibition and immunoglobulin therapy. Neuroscience (2009) 158(3):1074-89. doi:10.1016/j.neuroscience.2008.07.015
127. Van Beek J, Bernaudin M, Petit E, Gasque P, Nouvelot A, MacKenzie ET, et al. Expression of receptors for complement anaphylatoxins C3a and C5a following permanent focal cerebral ischemia in the mouse. Exp Neurol (2000) 161(1):373-82. doi:10.1006/exnr.1999.7273
128. Stephan AH, Barres BA, Stevens B. The complement system: an unexpected role in synaptic pruning during development and disease. Annu Rev Neurosci (2012) 35(1):369-89. doi:10.1146/annurev-neuro-061010-113810
129. Atkinson C, Zhu H, Qiao F, Varela JC, Yu J, Song H, et al. Complement-dependent P-selectin expression and injury following ischemic stroke. J Immunol (2006) 177(10):7266-74. doi:10.4049/jimmunol.177.10.7266
130. Rahpeymai Y, Hietala MA, Wilhelmsson U, Fotheringham A, Davies I, Nilsson A-K, et al. Complement: a novel factor in basal and ischemia-induced neurogenesis. EMBO J (2006) 25(6):1364-74. doi:10.1038/sj.emboj.7601004
131. Alawieh A, Elvington A, Zhu H, Yu J, Kindy MS, Atkinson C, et al. Modulation of post-stroke degenerative and regenerative processes and subacute protection by site-targeted inhibition of the alternative pathway of complement. J Neuroinflammation (2015) 12(1):247. doi:10.1186/s12974-015-0464-8
132. Elvington A, Atkinson C, Zhu H, Yu J, Takahashi K, Stahl GL, et al. The alternative complement pathway propagates inflammation and injury in murine ischemic stroke. J Immunol (2012) 189(9):4640-7. doi:10.4049/jimmunol.1201904
133. Mack WJ, Ducruet AF, Hickman ZL, Garrett MC, Albert EJ, Kellner CP, et al. Early plasma complement C3a levels correlate with functional outcome after aneurysmal subarachnoid hemorrhage. Neurosurgery (2007) 61(2):255-61. doi:10.1227/01.NEU.0000255518.96837.8E
134. Cavusoglu E, Eng C, Chopra V, Ruwende C, Yanamadala S, Clark LT, et al. Usefulness of the serum complement component C4 as a predictor of stroke in patients with known or suspected coronary artery disease referred for coronary angiography. Am J Cardiol (2007) 100(2):164-8. doi:10.1016/j.amjcard.2007.02.075
135. José PJ, Forrest MJ, Williams TJ. Human C5a des Arg increases vascular permeability. J Immunol (1981) 127(6):2376-80.
136. Lundberg C, Marceau F, Hugli T. C5a-induced hemodynamic and hematologic changes in the rabbit. Role of cyclooxygenase products and polymorphonuclear leukocytes. Am J Pathol (1987) 128(3):471.
137. Muscari A, Bozzoli C, Puddu GM, Sangiorgi Z, Dormi A, Rovinetti C, et al. Association of serum C3 levels with the risk of myocardial infarction. Am J Med (1995) 98(4):357-64. doi:10.1016/S0002-9343(99)80314-3
138. Gelderblom M, Leypoldt F, Steinbach K, Behrens D, Choe C-U, Siler DA, et al. Temporal and spatial dynamics of cerebral immune cell accumulation in stroke. Stroke (2009) 40(5):1849-57. doi:10.1161/strokeaha.108.534503
139. Iadecola C, Anrather J. The immunology of stroke: from mechanisms to translation. Nat Med (2011) 17(7):796-808. doi:10.1038/nm.2399
140. Yilmaz A, Fuchs T, Dietel B, Altendorf R, Cicha I, Stumpf C, et al. Transient decrease in circulating dendritic cell precursors after acute stroke: potential recruitment into the brain. Clin Sci (2009) 118(2):147-57. doi:10.1042/cs20090154